Hepatitis C Drugs A Good Fit For Outcomes-Based Contracts, McClellan Tells Insurers
Executive Summary
The former CMS and FDA head suggested at an AHIP conference that performance-based payments could help pave the way for a new “pricing model” for specialty drugs in the U.S.
You may also be interested in...
FDA Scales Back Near-Term Goals For Sentinel Postmarket Data Network
FDA’s Janet Woodcock said the agency has not been able to overcome budgetary restrictions that hamper previously discussed plans to develop the Sentinel postmarket drug safety surveillance system into a much broader national resource.
Risk-Sharing Drug Rebate Contracts: Do They Live Up To The Hype?
Manufacturers and payers will continue to work on innovative pricing arrangements, roundtable panelists said, but they are likely to be less complex and resource intensive than many of the risk-sharing contracts announced to date, particularly in Europe.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.